Trial Profile
Open Label Extension Study to Evaluate the Safety, Tolerability and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Alzheimer's Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Sodium selenate (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- 19 Feb 2013 New trial record